To the editor, Chromosomal translocations leading to oncogenic fusions are increasingly being recognized as molecular drivers of gliomas [9] . Approximately 3% of glioblastomas (GBMs) carry a fusion involving fibroblast growth factor receptors (FGFR1/FGFR3) with the transforming acidic coiled-coil domains of TACC1 or TACC3. FGFR3-TACC3 fusion gliomas exhibit characteristic, histologic features, including monomorphous ovoid nuclei, nuclear palisading, perivascular pseudorosettes, an endocrinoid ("chicken-wire") capillary network, microcalcifications and FGFR3 expression [1] . FGFR3-TACC3 fusion gliomas are IDH1/IDH2-wildtype, and frequently (~75% of cases) have TERT promoter mutations or CDKN2A loss [1] . The histologic features of FGFR3-TACC3 fusion glioma are similar to those in the recently described polymorphous low-grade neuroepithelial tumor of the young (PLNTY) [2, 4] . In fact, the majority of PLNTYs in some series carry the FGFR3-TACC3 fusion. Although rare reports of PLNTY occurring in adults exist, the majority of PLNTYs occur in young patients [7] . Although FGFR3-TACC3 fusion gliomas share histologic features with PLNTY, and may also express CD34, the former typically exhibits high-grade features consonant with glioblastoma and has a mean age at diagnosis of 62 years [1].
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Here we describe two cases of infiltrating glioma with histologic features of FGFR3-TACC3 fusion glioma. Molecular characterization confirmed the presence of FGFR3p.K650 T, TERT promoter mutation, and FGFR3-TACC3 fusion in both cases. The cases call attention to an association between the FGFR3p.K650 T mutation and FGFR3-TACC3 fusion.
Case 1
A 51-year-old woman presented with a 2-year history of numbness and left arm pain, with negative spine imaging and peripheral neuropathy workup. Due to new paresthesia of the left hip, MR imaging (MRI) of the brain was performed, which showed T2 hyperintensity in the right insula, associated with edema and mild contrast enhancement. Microscopic examination of the resected tumor showed hypercellular brain parenchyma infiltrated by small round monomorphic cells with perinuclear clearing resembling oligodendroglioma, microcalcifications and perivascular pseudorosettes. Mitotic activity was inconspicuous, and computer-assisted quantitation yielded a Ki67 proliferation index of 7.6% (Fig. 1) . A diagnosis of oligodendroglioma, NOS, WHO grade II, was rendered following guidelines from the 2007 WHO classification system for tumors of the central nervous system (CNS), which was in force at the time of diagnosis. Fluorescence in situ hybridization (FISH) analysis for chromosomal arms 1p and 19q was negative for codeletion. The patient was treated with intensity-modulated radiation therapy (IMRT) to a total dose of 50.4Gy in 28 fractions, together with 12 cycles of temozolomide chemotherapy.
The patient was placed on surveillance imaging every 3 months and was stable until~3 years after presentation when a new area of contrast enhancement was identified adjacent to the resection cavity. Resection of the recurrent lesion was performed. Microscopic examination showed a compact, densely cellular glioma with morphologic features associated with the recently-described FGFR3-TACC3 fusion glioma [3, 6, 9] . The characteristic features evident in this case include a population of glioma cells with monomorphous ovoid nuclei, nuclear palisading and enfilading, thin parallel cytoplasmic processes, endocrinoid capillary network, microcalcifications and desmoplasia ( Fig. 1 ) [1] . The tumor from the second resection showed foci of vascular proliferation, correlating with the presence of contrast enhancement on the preoperative MRI. In contrast to the low proliferation index of the initial tumor, the recurrent tumor showed a Ki67 index of 30.3%. GFAP was expressed in perivascular cell processes of the tumor cells, EMA was negative, and expression of the ATRX protein was retained.
Next generation sequencing analysis (NGS) for mutations (134 genes), copy number variations (47 genes), and fusions (51 genes), was performed on the recurrent tumor. The results showed FGFR3p.K650 T, NF1p.F443C and TERTc.-124C > T mutations, as well as the FGFR3-TACC3 (COSF1353) fusion. These findings prompted analysis of the initial tumor. NGS analysis revealed only the presence of FGFR3p.K650 T mutation; NF1 and TERT mutations were not identified in the tumor from the first surgery (Table 1) . Conventional RT-PCR with FGFR3 and TACC3 specific primers (5′-AGGAGCTCTTCAAGCTGCTG-3′ and 5′-GGGG GTCGAACTTGAGGTAT-3′) generated a product of the expected size (225 bp) and confirmed the FGFR3-TACC3 fusion in the original tumor. 
Case 2
A 75-year-old female presented to our institution for evaluation of treatment options after a diagnosis of malignant glioma. H&E-stained sections from the biopsy showed a high-grade glial tumor with microcalcifications, perivascular pseudorosettes, elevated mitotic activity, vascular proliferation and necrosis with pseudopalisading (Fig. 2) . The tumor cells expressed GFAP, punctate EMA staining was present in several areas, and automated quantitation yielded a Ki67 proliferation index of~50%. The final diagnosis was glioblastoma, IDH-wildtype, WHO grade IV, based on the 2016 WHO classification of CNS tumors. Subsequent NGS analysis (same assay as described above) showed the presence of FGFR3p.K650 T and TERTc.-146C > T mutations, and an FGFR3-TACC3 fusion (COSF1348). The patient was treated with concurrent radiation and temozolomide. These cases illustrate the morphologic and molecular alterations of FGFR3-TACC3 fusion glioma. The molecular alterations emphasize several important points. (1) The strong association between FGFR3-TACC3 fusion and TERT promoter mutations. (2) The novel concurrent association between the FGFR3p.K650 T point mutation and the FGFR3-TACC3 fusion. This association has clinical importance because analysis for gene mutations is more commonly done than fusion analysis. The presence of FGFR3p.K650 T should alert the physician to the possibility of an FGFR3-TACC3 fusion. Previous studies of FGFR3-TACC3 fusion gliomas have focused on fusion detection, with minimal simultaneous mutation analysis.
It is therefore unclear if FGFR3p.K650 T is uniformly associated with the FGFR3-TACC3 fusion, although these examples suggest that may be the case. Given the existence of FGFR inhibitors, some which are being evaluated for the treatment of glioblastoma, recognition of the association between these two molecular alterations is important [5] . (3) The case data presented here supports a potential pathway to progression in FGFR3-TACC3 fusion glioma, from low-grade to high-grade, through acquisition of a TERT promoter mutation.
FGFR3 alterations are common in bladder cancers (~35% of cases) but extremely rare in brain tumors. FGFR3 codon 650 is 1 of 3 somatic mutation hotspots in this gene, although it is the least commonly affected (COSMIC). In COSMIC, there are~200 reports of mutations at FGFR3p.650; in total there are 3 high-grade astrocytomas with an FGFR3 p.K650 T mutation. The FGFR3 p.K650 T mutation is reported as a pathogenic mutation in Clinvar and GeneReviews. Also, the FATHMM in silico method gives this mutation a pathogenic score of 0.98; scores of > 0.7 are considered pathogenic and are reported as such in COSMIC. We were unable to find reports with functional data on the FGFR3 p.K650 T mutation. However, FGFR3 p.K650E has been associated with constitutive activation of the receptor [8] .
There is a noteworthy similarity between the histology of PLNTY and FGFR3-TACC3 fusion glioma. There are also similarities in their genetic alterations, given that the FGFR3-TACC3 fusion has been described in both entities. However, there is a significant difference in the e Areas of the tumor showed an endocrinoid capillary network and microcalcifications. f Necrosis with pseudopalisading, consistent with glioblastoma, is also present mean age at diagnosis between PLNTY and FGFR3-TACC3 fusion glioma, being 17.6 years (4-32) vs. 67 (35-87) years, respectively. Also, TERT promoter mutations and CDNK2A loss frequently occur in FGFR3-TACC3 fusion gliomas, whereas these alterations have not been reported in PLNTY.
Suspicion for the FGFR3-TACC3 fusion in the two present cases began with microscopic examination of H&E-stained sections, which elicited fusion testing. Recognition of the characteristic histologic feature set of FGFR3-TACC3 fusion glioma (and PLNTY) prompted molecular testing in both cases. In an era in which stratification and treatment of brain tumors is increasingly being guided by molecular information, recognizing the possibility of an FGFR3-TACC3 fusion in an infiltrating astrocytoma is critical, and may result in significant therapeutic impact.
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